查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1644234

全球放射腫瘤學市場

Radiotheranostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 168 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球放射腫瘤學市場規模將達 224 億美元

2024 年全球放射治療市場規模估計為 104 億美元，預計到 2030 年將達到 224 億美元，2024-2030 年分析期間的複合年成長率為 13.6%。標靶診斷模式是報告中分析的細分市場之一，預計到分析期結束時複合年成長率為 7.5%，達到 98 億美元。在分析期內，標靶治療領域預計將以 20.5% 的複合年成長率成長。

美國市場規模估計為 27 億美元，中國市場預計複合年成長率為 13.0%

預計 2024 年美國放射腫瘤學市場價值將達到 27 億美元。中國是世界第二大經濟體，預計到 2030 年市場規模將達到 35 億美元，2024-2030 年分析期間的複合年成長率為 13.0%。其他值得注意的區域市場包括日本和加拿大，預計在分析期間的複合年成長率分別為 11.7% 和 12.1%。在歐洲，德國的複合年成長率預計為 10.4%。

全球放射腫瘤學市場 - 主要趨勢和促進因素摘要

是什麼讓放射治療成為精準醫療的前沿？

放射腫瘤學是一種結合診斷影像和標靶放射治療的尖端方法，它正在成為個人化醫療領域的變革者。這種雙重功能技術可以精確識別腫瘤並使用放射性藥物進行客製化治療，最大限度地減少對健康組織的損害。隨著全球癌症發生率持續上升，放射治療因其更有效、侵入性更小的治療方法而越來越受歡迎。此外，放射治療與核子醫學的結合正在徹底改變腫瘤學，為患者提供更好的治療效果和生活品質。隨著精準醫療的不斷轉變，放射療法已成為對抗癌症的重要工具。

科技創新如何重新定義放射治療的範圍？

技術進步在擴大放射腫瘤學能力方面發揮了核心作用。新型放射性藥物（如鎦-177和錒-225等放射性同位素）的開發使得診斷影像和治療更加精確。 PET/CT、SPECT/CT等分子成像技術的進步正在提高疾病診斷和治療監測的準確性。此外，人工智慧和機器學習也被納入放射治療工作流程，以增強影像解釋並最佳化治療計劃。這些創新不僅促進了臨床成功，也鼓勵製藥公司和研究機構大力投資放射腫瘤學開發。

放射腫瘤學有哪些新的應用和趨勢？

放射療法的應用正在腫瘤學之外迅速擴展，在前列腺癌和神經內分泌腫瘤的治療中取得了顯著的成功。研究人員正在探索利用針對特定生物途徑的能力來治療其他疾病（如心血管疾病和某些感染疾病）的可能性。一種新興趨勢是聯合治療，將免疫療法與化療結合以增強治療效果。此外，放射性藥物生產和供應鏈物流的進步正在解決可擴展性挑戰，並確保這些治療方法能夠更廣泛地提供給不同醫療環境中的患者。

推動放射腫瘤學市場快速成長的因素是什麼？

放射腫瘤學市場的成長受到多種因素的推動。全球癌症發生率的不斷上升對創新治療方法的需求日益成長，使得放射腫瘤學成為關注的重點領域。放射性藥物開發和分子成像技術的重大進展正在提高這些治療方法的有效性和可及性。新興市場對核醫基礎設施的投資增加和醫療保健預算的擴大也推動了市場的成長。此外，患者和醫療保健提供者對個人化治療方法的日益偏好也推動了放射腫瘤學的採用。監管支持和優惠的報銷政策進一步促進了這項有前景的技術的廣泛應用，鞏固了其在未來精準醫療中的作用。

部分

方式（標靶診斷、標靶治療）；放射性同位素（鎦-177、鎵-68、碘-131、碘-123、其他）；應用（腫瘤學應用、非腫瘤學應用）

受訪公司範例（值得關注的36家公司）

  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics
  • Bayer AG
  • Cardinal Health, Inc.
  • Curium
  • Ellipses Pharma
  • GE Healthcare
  • ImmunoMet Therapeutics
  • Life Healthcare
  • Life Molecular Imaging GmbH

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP32753

Global Radiotheranostics Market to Reach US$22.4 Billion by 2030

The global market for Radiotheranostics estimated at US$10.4 Billion in the year 2024, is expected to reach US$22.4 Billion by 2030, growing at a CAGR of 13.6% over the analysis period 2024-2030. Targeted Diagnostics Modality, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$9.8 Billion by the end of the analysis period. Growth in the Targeted Therapeutics Modality segment is estimated at 20.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 13.0% CAGR

The Radiotheranostics market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 12.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Global Radiotheranostics Market - Key Trends & Drivers Summarized

What Is Propelling Radiotheranostics to the Forefront of Precision Medicine?

Radiotheranostics, a cutting-edge approach that combines diagnostic imaging with targeted radiotherapy, is emerging as a game-changer in personalized medicine. This dual-function technology enables precise tumor identification and tailored treatment using radiopharmaceutical agents, minimizing damage to healthy tissues. As cancer prevalence continues to rise globally, radiotheranostics is gaining traction for its ability to provide more effective and less invasive treatment options. Furthermore, the integration of radiotheranostics into nuclear medicine is revolutionizing oncology, offering patients better outcomes and quality of life. The growing shift toward precision medicine is reinforcing its adoption, making radiotheranostics a pivotal tool in the fight against cancer.

How Is Innovation Redefining the Scope of Radiotheranostics?

Technological advancements are playing a central role in expanding the capabilities of radiotheranostics. The development of novel radiopharmaceuticals, such as theranostic isotopes like lutetium-177 and actinium-225, is enabling higher precision in both imaging and therapy. Advances in molecular imaging technologies, including PET/CT and SPECT/CT, are improving the accuracy of disease diagnosis and treatment monitoring. Additionally, artificial intelligence and machine learning are being incorporated into radiotheranostic workflows to enhance imaging interpretation and optimize treatment planning. These innovations are not only driving clinical success but also encouraging pharmaceutical companies and research institutions to invest heavily in radiotheranostics development.

What Are the Emerging Applications and Trends in Radiotheranostics?

The application of radiotheranostics is rapidly expanding beyond oncology, where it has demonstrated remarkable success in treating prostate cancer and neuroendocrine tumors. Researchers are exploring its potential in addressing other diseases, such as cardiovascular conditions and certain infectious diseases, by leveraging its ability to target specific biological pathways. An emerging trend is the use of combination therapies, where radiotheranostics is paired with immunotherapy or chemotherapy to amplify treatment efficacy. Furthermore, advancements in radiopharmaceutical production and supply chain logistics are addressing scalability challenges, ensuring that these therapies are more widely available to patients across diverse healthcare settings.

What Drives the Rapid Growth in the Radiotheranostics Market?

The growth in the Radiotheranostics market is driven by several factors. Increasing cancer incidence worldwide has heightened the need for innovative treatment modalities, making radiotheranostics a critical focus area. Significant advancements in radiopharmaceutical development and molecular imaging technologies have enhanced the efficacy and accessibility of these treatments. Rising investments in nuclear medicine infrastructure and expanding healthcare budgets in developing regions are also accelerating market growth. Additionally, the growing preference for personalized treatment approaches among both patients and healthcare providers is boosting the adoption of radiotheranostics. Regulatory support and favorable reimbursement policies further contribute to the widespread adoption of this promising technology, cementing its role in the future of precision medicine.

SCOPE OF STUDY:

The report analyzes the Radiotheranostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Modality (Targeted Diagnostics, Targeted Therapeutics); Radioisotope (Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope, Other Radioisotopes); Application (Oncology Application, Non-Oncology Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics
  • Bayer AG
  • Cardinal Health, Inc.
  • Curium
  • Ellipses Pharma
  • GE Healthcare
  • ImmunoMet Therapeutics
  • Life Healthcare
  • Life Molecular Imaging GmbH

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Economic Frontiers: Trends, Trials & Transformations
    • Radiotheranostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Focus on Precision Medicine and Targeted Therapies Drives Market Growth
    • Rising Adoption of Theranostic Agents in Oncology Treatments Propels Industry Expansion
    • Growing Use of PET Imaging in Radiotheranostic Applications Fuels Demand
    • Expansion of Nuclear Medicine Facilities Supporting Radiotheranostics Enhances Market Potential
    • Advancements in Radiolabeling Technologies for Improved Accuracy Propel Technological Growth
    • Integration of AI Tools in Radiotheranostic Imaging and Diagnostics Drives Innovation
    • Increasing Demand for Personalized Treatment Protocols in Cancer Care Boosts Adoption Rates
    • Collaboration Between Pharmaceutical and Diagnostic Companies in Radiotheranostics Drives Market Expansion
    • Role of Radiotheranostics in Emerging Immuno-Oncology Treatments Fuels New Opportunities
    • Rising Utilization of Theranostics for Non-Oncological Conditions Enhances Market Demand
    • Growing Interest in Dual-Modality Imaging Techniques Drives Technological Advancements
    • Investments in R&D for Novel Radiotheranostic Compounds Propel Industry Innovation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Radiotheranostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Radiotheranostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Radiotheranostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Targeted Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Targeted Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Targeted Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Lutetium-177 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Lutetium-177 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Gallium-68 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Gallium-68 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Iodine-131 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Iodine-131 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Iodine-123 Radioisotope by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Iodine-123 Radioisotope by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Other Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Non-Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Non-Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • CANADA
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • JAPAN
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • CHINA
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 40: China Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • EUROPE
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Radiotheranostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • FRANCE
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 54: France Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • GERMANY
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • ITALY
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • UNITED KINGDOM
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 72: UK Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Radiotheranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Radiotheranostics by Modality - Targeted Diagnostics and Targeted Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Radiotheranostics by Modality - Percentage Breakdown of Value Sales for Targeted Diagnostics and Targeted Therapeutics for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Radiotheranostics by Radioisotope - Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Radiotheranostics by Radioisotope - Percentage Breakdown of Value Sales for Lutetium-177 Radioisotope, Gallium-68 Radioisotope, Iodine-131 Radioisotope, Iodine-123 Radioisotope and Other Radioisotopes for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Radiotheranostics by Application - Oncology Application and Non-Oncology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Radiotheranostics by Application - Percentage Breakdown of Value Sales for Oncology Application and Non-Oncology Application for the Years 2025 & 2030

IV. COMPETITION